[The antitryptic activity of the blood serum in patients with chronic bronchitis and lung cancer in relation to the phenotypic variant of the alpha-1 proteinase inhibitor].

Blood serum was studied for its antitryptic activity in 161 patients with chronic bronchitis, 87 individuals with malignant tumors of the respiratory organs, 70 blood donors, with regard to phenotypic variant of alpha 1-inhibitor of proteinases. Difference was revealed in antitryptic activity, associated with the particular features of the pathologic process and phenotypic variant of the inhibitor. There exists in the carriers of homozygote latent insufficiency of the inhibitory defence of the organism against the proteolytic effects.